BURL CONCEPTS ANNOUNCES FDA 510(K) CLEARANCE FOR FOQUS™ ULTRASOUND SYSTEM FOR RAPID, AUTOMATED PATENT FORAMEN OVALE (PFO) SCREENING

SAN DIEGO, Nov. 19, 2026 /PRNewswire/ -- BURL Concepts, a private medtech company developing an automated and affordable test for evaluating cerebral blood flow and rapid detection of emboli, announced today that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the FOQUS™ ultrasound system, powered by SONAS®, a medical ultrasound device indicated for use for measuring the occurrence of transient embolic signals in the brain blood stream.

FOQUS is a portable, automated transcranial ultrasound system that monitors the entire brain for the appearance of emboli. A standard Patent Foramen Ovale (PFO) ‘bubble test’ will be the first clinical application of FOQUS when an air bubble solution is administered intravenously and acoustic signals generated by air bubbles are detected as they pass through the brain’s circulation. The detection of such an acoustic signal helps physicians identify the presence of a Right-To-Left Shunt (RLS), which is commonly caused a PFO, or a hole between the left and right atria of the heart that failed to close after birth. Approximately 40 to 50% of patients with cryptogenic stroke have a PFO. 

Sign up for Blog Updates